Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 8/20 | 0.58 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.58 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.58 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.58 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.58 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GABRP | O00591 | 1/20 | 0.58 |
| ▸ | GABRD | O14764 | 1/20 | 0.58 |
| ▸ | IKBKB | O14920 | 1/20 | 0.58 |
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.58 |
| ▸ | TOP1 | P11387 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18427910 | 0.86 | ACHE (0.58) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL24817 | 0.77 | ALDH1A1 (0.54) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL1844840 | 0.76 | CHUK (0.58) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL30322777 | 0.74 | CHUK (0.78) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL2388664 | 0.74 | ALDH1A1 (0.39) | KDM4EALDH1A1HPGDSMN1; SMN2ACHE | |
| SCHEMBL12396541 | 0.74 | CHUK (0.78) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL9486853 | 0.74 | CHUK (1.00) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Carbazole SCHEMBL18684843 | 0.74 | CHUK (1.00) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL25834 | 0.74 | CHUK (1.00) | CHUKGABRA1GABRG2GABRB3GABRA5 | |
| Norharmane SCHEMBL29370219 | 0.74 | CHUK (1.00) | CHUKGABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49118-E1 | Material for organic electroluminescence device and electroluminescence device employing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2022-06-28 | — | — | US | claimed |
| US-20050171101-A1 | Phenanthridinones as parp inhibitors | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-08-04 | — | — | US | claimed |
| EP-1487800-A1 | PHENANTHRIDINONES AS PARP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | claimed |
| WO-2003080581-A1 | PHENANTHRIDINONES AS PARP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-02 | — | — | WO | claimed |
| US-RE49118-E1 | Material for organic electroluminescence device and electroluminescence device employing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2022-06-28 | — | — | US | disclosed |
| EP-3736266-A1 | COMPOUND SIMULTANEOUSLY INHIBITING LSD1 AND HDAC TARGETS AND APPLICATION THEREOF | Peking University Shenzhen Graduate School (CN) | 2020-11-11 | — | — | EP | disclosed |
| US-20200331882-A1 | COMPOUND FOR SIMULTANEOUSLY INHIBITING LSD1 AND HDAC TARGETS AND APPLICATION THEREOF | PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) | 2020-10-22 | — | — | US | disclosed |
| US-9700633-B2 | Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof | JENKEM TECHNOLOGY CO., LTD., TIANJIN BRANCH (CN) | 2017-07-11 | — | — | US | disclosed |
| EP-2803665-B1 | SYNTHESIS OF POLYHYDROXY BENZOPYRAN KETONE COMPOUND AND ANTI-TUMOR EFFECT THEREOF | BEIJING SHENOGEN PHARMA GROUP LTD (CN) | 2017-05-10 | — | — | EP | disclosed |
| US-9221781-B2 | Synthesis of polyhydroxy chromenone compounds and their anti-tumor effects | BEIJING SHENOGEN PHARAM GROUP LTD. (CN) | 2015-12-29 | — | — | US | disclosed |
| US-20150359900-A1 | CONJUGATES OF WATER SOLUBLE POLYMER-AMINO ACID OLIGOPEPTIDE-DRUG, PREPARATION METHOD AND USE THEREOF | JENKEM TECHNOLOGY CO. LTD., TIANJIN BRANCH (CN) | 2015-12-17 | — | — | US | disclosed |
| US-9082995-B2 | Organic EL element and organic EL material-containing solution | IDEMITSU KOSAN CO., LTD. (JP) | 2015-07-14 | — | — | US | disclosed |
| EP-1487800-A1 | PHENANTHRIDINONES AS PARP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004096811-A1 | PDE9 INHIBITORS FOR TREATING TYPE 2 DIABETES, METABOKIC SYNDROME, AND CARDIOVASCULAR DISEASE | PFIZER PRODUCTS INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096768-A1 | ANTI-DIABETIC AGENTS | PFIZER PRODUCTS INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040220229-A1 | insulin resistance; central nervous system disorders; vision defects; anticholesterol agents;antilipemic agents; antiischemic agents | PFIZER INC | 2004-11-04 | — | — | US | disclosed |
| WO-2004085439-A1 | SUBSTITUTED 4-AMINO[1,2,4]TRIAZOLO[4,3-A]QUINOXALINES | PFIZER PRODUCTS INC. (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192698-A1 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | PFIZER INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2003080581-A1 | PHENANTHRIDINONES AS PARP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171101-A1 | Phenanthridinones as parp inhibitors | PARP1, PARP11, PARP2 | CHUK 124/4885GABRA1 3643/4885GABRG2 4241/4885 |
| US-20150359900-A1 | CONJUGATES OF WATER SOLUBLE POLYMER-AMINO ACID OLIGOPEPTIDE-DRUG, PREPARATION METHOD AND USE THEREOF | SLC7A1, NPPA, PEPD | CHUK 3008/4885GABRA1 3259/4885GABRG2 4030/4885 |
| US-20040220229-A1 | insulin resistance; central nervous system disorders; vision defects; anticholesterol agents;antilipemic agents; antiischemic agents | IRS1, INSR, GPR119 | CHUK 178/4885GABRA1 2846/4885GABRG2 3725/4885 |
| US-20200331882-A1 | COMPOUND FOR SIMULTANEOUSLY INHIBITING LSD1 AND HDAC TARGETS AND APPLICATION THEREOF | HDAC1, HDAC3, HDAC11 | CHUK 282/4885GABRA1 595/4885GABRG2 593/4885 |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PDE9A, PDE2A, PDE12 | CHUK 964/4885GABRA1 3842/4885GABRG2 3980/4885 |
| US-20040192698-A1 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | CYP4B1, CYP3A4, CYP1B1 | CHUK 2447/4885GABRA1 1217/4885GABRG2 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.